Biogen Pharma — 360° view

Biogen Pharma, a company in the Other Financial Services industry, reported revenue of ₹0.28 crore and net profit of ₹0.26 crore for the September 2026 quarter.

Biogen Pharma (BSE: BIOGEN) closed at ₹0.29 on 20 Nov 2026, down 56.7% over the past year. Its market capitalisation is ₹31 crore and it trades at 52.7 times earnings.

Share price
₹0.29 (20 Nov 2026)
Market cap
₹31 Cr (20 Nov 2026)
P/E
52.66 (20 Nov 2026)
Revenue
₹0 Cr (September 2026 quarter)
Net profit
₹0 Cr (September 2026 quarter)
ROCE
1.01% (FY26)
ROE
0.90% (FY26)
Book value
₹0.95 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹0.72 / ₹0.23 (20 Nov 2026)
1-year return
-56.7% (to 20 Nov 2026)
Sector
Financial Services
Industry
Other Financial Services
Symbol
BSE: BIOGEN

Incorporated in 1995, Biogen Pharmachem Industries Ltd is in the business of trading in shares and securities.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.